<?xml version="1.0" encoding="UTF-8"?>
<p>Ebola viruses have for the last forty years been responsible for a number of outbreaks of Ebola virus disease (EVD) in humans (
 <xref rid="bib99" ref-type="bibr">Pattyn et al., 1977</xref>), with high case fatality rates typically around 60â€“70%, but potentially reaching as high as 90% (
 <xref rid="bib31" ref-type="bibr">Feldmann and Geisbert, 2011</xref>). The most recent outbreak began in Guinea in December 2013 (
 <xref rid="bib2" ref-type="bibr">Baize et al., 2014</xref>; 
 <xref rid="bib7" ref-type="bibr">Bausch and Schwarz, 2014</xref>) and has subsequently spread to Liberia, Sierra Leone and Nigeria (
 <xref rid="bib27" ref-type="bibr">ECDC, 2014</xref>). The unprecedented size and scale of this ongoing outbreak has the potential to destabilise already fragile economies and healthcare systems (
 <xref rid="bib30" ref-type="bibr">Fauci, 2014</xref>), and fears of international spread of a Category A Priority Pathogen (
 <xref rid="bib92" ref-type="bibr">NIH, 2014</xref>) have made this a massive focus for international public health (
 <xref rid="bib19" ref-type="bibr">Chan, 2014</xref>). This has led to the current outbreak being declared a Public Health Emergency of International Concern on the 8 August 2014 (
 <xref rid="bib14" ref-type="bibr">Briand et al., 2014</xref>; 
 <xref rid="bib45" ref-type="bibr">Gostin et al., 2014</xref>; 
 <xref rid="bib144" ref-type="bibr">WHO, 2014d</xref>).
</p>
